Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Immunic AG has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters span 3 examiners and 3 art units, showing distinct examination contexts across the portfolio.
MOORE, SUSANNA is the busiest examiner, with 1 pending matter. Prosecution management should track each assignment independently while preserving a consistent portfolio position.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOORE, SUSANNA | 1 | 68.0% | +31.6% |
| CHO, DAVID H | 1 | 31.9% | +67.0% |
| VAJDA, KRISTIN ANN | 1 | 83.8% | +11.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18576533 | METHODS FOR TREATING CANCER | VAJDA, KRISTIN ANN | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705970 | MEDICAL USE OF N4-HYDROXY CITICOLINE COMPOUNDS | CHO, DAVID H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18719384 | DHODH INHIBITORS CONTAINING A CARBOXYLIC ACID BIOISOSTERE | MOORE, SUSANNA | — |
| 18705970 | MEDICAL USE OF N4-HYDROXY CITICOLINE COMPOUNDS | CHO, DAVID H | — |
| 18576533 | METHODS FOR TREATING CANCER | VAJDA, KRISTIN ANN | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1693 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18719384 | DHODH INHIBITORS CONTAINING A CARBOXYLIC ACID BIOISOSTERE | MOORE, SUSANNA | 1624 | §112 | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18705970 | MEDICAL USE OF N4-HYDROXY CITICOLINE COMPOUNDS | CHO, DAVID H | 1693 | §103§112 | Non-Final OA | — | Pending | Apr 29, 2024 |
| 18576533 | METHODS FOR TREATING CANCER | VAJDA, KRISTIN ANN | 1622 | §103DP | Non-Final OA | — | Pending | Jan 04, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImmunic AG has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Susanna Moore has the most, with 1 of Immunic AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
